多索茶碱联合噻托溴铵粉治疗慢性阻塞性肺疾病患者的效果

Effects of Doxofylline combined with Tiotropium bromide powder in treatment of patients with chronic obstructive pulmonary disease

目的:观察多索茶碱联合噻托溴铵粉治疗慢性阻塞性肺疾病(COPD)患者的效果。方法:选取2022年2月至2024年2月该院收治的70例COPD患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各35例。对照组给予多索茶碱治疗,观察组在对照组基础上联合噻托溴铵粉治疗,比较两组临床疗效,治疗前后炎性因子[C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)]水平、肺功能[第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)、呼气峰流速(PEF)、FEV_(1)/FVC]水平,以及不良反应发生率。结果:观察组治疗总有效率为94.29%(33/35),高于对照组的74.29%(26/35),差异有统计学意义(P<0.05);治疗后,两组CRP、TNF-α、IL-6水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组FEV_(1)、FVC、FEV_(1)/FVC、PEF水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:多索茶碱联合噻托溴铵粉治疗COPD患者,可提高临床疗效,减轻机体炎症反应,改善肺功能,效果优于单纯多索茶碱治疗。

Objective:To observe effects of Doxofylline combined with Tiotropium bromide powder in treatment of patients with chronic obstructive pulmonary disease(COPD).Methods:A prospective study was conducted on 70 patients with COPD admitted to the hospital from February 2022 to February 2024.According to the random number table method,they were divided into control group and observation group,35 cases in each group.The control group was treated with Doxofylline,while the observation group was treated with Tiotropium bromide powder on the basis of that of the control group.The clinical efficacy,the levels of inflammatory factors[C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)]and lung function[forced expiratory volume in one second(FEV_(1)),forced vital capacity(FVC),peak expiratory flow(PEF),FEV_(1)/FVC]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 94.29%(33/35),which was higher than 74.29%(26/35)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CRP,TNF-αand IL-6 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of FEV_(1),FVC,FEV_(1)/FVC and PEF in the two groups were higher than those before the treatment,those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Doxofylline combined with Tiotropium bromide powder in the treatment of the COPD patients can improve the clinical efficacy,reduce the body’s inflammatory response,and improve the lung function.Moreover,it is superior to simple Doxofylline treatment.